Hint mode is switched on Switch off

Mineralys Therapeutics, ordinary share
MLYS, US6031701013

Add a stock to WL
Choose all Reset all
Mineralys Therapeutics, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Get access Watch full tour

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

Profile
Mineralys Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Mineralys Therapeutics offers aldosterone synthase inhibitor (ASI) that we are initially developing for ...
Mineralys Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Mineralys Therapeutics offers aldosterone synthase inhibitor (ASI) that we are initially developing for the treatment of patients with uncontrolled hypertension.
Show more Hide
  • Issuer
  • Full borrower / issuer name
    Mineralys Therapeutics Inc
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    MLYS
  • Placement
    10.02.2023
  • Lock up period
    180
  • Number of papers
    12,000,000
  • Volume of raised funds
    192 mln USD
  • Placement share
    30.72%
  • Final placement price
    16 USD
  • Price change since placement date
    64.75%
  • By capitalization
    624.91 mln USD
Other placements of the issuer
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    MLYS
  • Placement
    12.03.2025
  • Lock up period
    180
  • Number of papers
    12,962,962
  • Volume of raised funds
    175 mln USD
  • Placement share
    20.65%
  • Final placement price
    13.5 USD
  • Price change since placement date
    95.26%
  • By capitalization
    847.6 mln USD

IFRS/US GAAP reports

2025
I q eng
III q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
Show all Hide

Related Stock indices

Indicators

News

02/06/2026 Mineralys Therapeutics: Of This Current Report On Form 8k Regarding The Loan Agreement Is Incorporated By Reference Into This Item 2.03
14/03/2026 Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Overview and Financial Insights
02/09/2025 Mineralys Therapeutics: Other Events, Financial Statements And Exhibits
02/09/2025 Mineralys Therapeutics: Other Events
22/05/2025 Mineralys Therapeutics: Submission Of Matters To A Vote Of Security Holders
All organization news

Holders

Industry Leaders

Registration is required to get access.